<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72994">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02155439</url>
  </required_header>
  <id_info>
    <org_study_id>140260M</org_study_id>
    <secondary_id>2013-004512-22</secondary_id>
    <nct_id>NCT02155439</nct_id>
  </id_info>
  <brief_title>Treatment of Keloidscars With Intralesional Triamcinolone and 5-fluorouracil Injections-prospective, Randomized, Controlled Trial - Pilot Study</brief_title>
  <official_title>Treatment of Keloidscars With Intralesional Triamcinolone and 5-fluorouracil Injections-prospective, Randomized, Controlled Trial - Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tampere University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of study is examine the efficacy of intralesional 5-fluorouracil injections in
      keloid disease treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptoms (pain, itching) of keloids and appearance of keloid</measure>
    <time_frame>baseline and one year</time_frame>
    <description>Change from baseline symptoms of scars baseline at one year with POSAS score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration change of hemoglobin and melanin</measure>
    <time_frame>0 week, 3 week, 6 week, 12 week, 1 year</time_frame>
    <description>Camera analysis with spectrocutometry</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Inflammatory cells and their different populations, blood vessel density, fibroplast proliferation (KI67) and estrogenreseptor</measure>
    <time_frame>0 week, 3 week, 6 week, 12 week, 1 year</time_frame>
    <description>immonuhistochemical analysis with punch biopsy</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Keloidscars</condition>
  <arm_group>
    <arm_group_label>Triamcinolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>kortikosteroid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5-fluorouracil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>antimitotic drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <description>antimitotic drug</description>
    <arm_group_label>Triamcinolone</arm_group_label>
    <other_name>Fluorouracil Accord</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone</intervention_name>
    <arm_group_label>5-fluorouracil</arm_group_label>
    <other_name>Lederspan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Person who has a keloidscar which could be treated with injection treatment

        Exclusion Criteria:

          -  Pregnancy, lactating, renal or liver failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kristiina E Hietanen</last_name>
    <phone>+358331169469</phone>
    <email>kristiina.hietanen@pshp.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tampere university hospital</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristiina E Hietanen</last_name>
      <phone>+358331165881</phone>
      <email>kristiina.hietanen@pshp.fi</email>
    </contact>
    <investigator>
      <last_name>Kristiina E Hietanen, ms</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 21, 2016</lastchanged_date>
  <firstreceived_date>April 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tampere University Hospital</investigator_affiliation>
    <investigator_full_name>Kristiina Hietanen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Prospective, randomized controlled trial - pilot study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
